GlassScriptPhysician profile
Lance Reinherz
NPI 1134173750
$4,215.21
in general payments reported to CMS, 2019-2025
32 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.40 · 2020: $507 · 2021: $873 · 2022: $555 · 2023: $927 · 2024: $758 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096 · Education: $89.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.85 |
| Education | $89.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $591.04 | 2019-2025 | |
| Pfizer INC. | $440.28 | 2020-2025 | |
| Abbott Laboratories | $371.12 | 2019-2024 | Mitraclip, Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $279.66 | 2020-2025 | Abilify, Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $254.03 | 2019-2024 | |
| Cvrx, INC. | $249.69 | 2021-2023 | Barostim Neo System |
| Amarin Pharma, INC. | $246.06 | 2020-2021 | |
| Amgen INC. | $241.69 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $232.91 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.78 | 2021-2025 | Jardiance |
| Heartflow, INC. | $163.36 | 2025 | |
| Novo Nordisk INC | $160.44 | 2024-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $106.47 | 2020-2025 | Farxiga |
| Impulse Dynamics (USA) INC. | $82.99 | 2023 | Optimizer |
| Arbor Pharmaceuticals, INC. | $77.46 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $75.81 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $52.54 | 2024 | |
| Merck Sharp & Dohme LLC | $47.61 | 2022-2023 | Verquvo |
| Medtronic, INC. | $44.66 | 2023 | Linq II |
| Irhythm Technologies, INC. | $42.71 | 2022-2023 | Zio Xt Patch |
| Kowa Pharmaceuticals America, INC. | $39.69 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $29.93 | 2023-2025 | Edarbi, Edarbi |
| Daiichi Sankyo INC. | $25.66 | 2025 | Injectafer |
| Cleerly, INC. | $23.31 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Regeneron Healthcare Solutions, INC. | $22.54 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $20.57 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.22 | 2025 | Opsumit, Uptravi |
| Tactile Systems Technology INC | $16.72 | 2019 | |
| Medtronic Vascular, INC. | $16.26 | 2020 | |
| Baxter Healthcare | $16.23 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $15.77 | 2024 | Eluvia |
| Bardy Diagnostics, INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Reinherz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.